ADMA
ADMA Biologics, Inc.
Set alert
- YTD
- -37.45%
- 1 year
- -25.28%
- Open
- 11.85
- Prev close
- 11.75
- Mkt cap
- 2.56B
- Vol
- 2.46M
- Avg vol
- 2.68M
- EPS
- 0.70
- P/E
- 16.30
- Div yield
- 0.00%
More statistics
- Low
- 11.37
- High
- 11.90
- Forward P/E
- 12.07
- Beta
- 0.69
- Short ratio
- 5.82
- Inst. own
- 92.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 9.97
- 200-d avg
- 10.99
- 1y target
- 17.00
Discussion (150)
Sign in to join the discussion
Eugene Lin ADMA 4 years ago #1I am an ADMA long hauler. It is inevitable that the rapid rise in revenue will translate into improved shareholder value. Almost 100% rise in annual revenue and multiple FDA approvals are bullish indicators.
Eugene Lin ADMA 4 years ago #2$ADMA Preliminary Fourth Quarter and Full Year 2021 Revenues and 2022 Strategic Outlook should be available soon.
Eugene Lin ADMA 4 years ago #3$ADMA ADMA Biologics should be announcing preliminary fourth quarter and full year 2021 revenues sometime this month. It could be a positive catalyst.
Eugene Lin ADMA 5 years ago #4$ADMA has estimated revenue between $20 million and $20.5 million in Q3. Explosive revenue growth.
Eugene Lin ADMA 5 years ago #5$ADMA I think Q3 report next month will show at least $20 million in revenue.
Eugene Lin ADMA 5 years ago #6$ADMA This stock will reward those with patience. Penny stock company with a high demand product and explosive revenue growth is a setup for a massive short squeeze. Just wait for the catalyst.
Eugene Lin ADMA 5 years ago #7$ADMA I have been trading ADMA stock since April 2020 and have made money every trade by buying on the big dips and selling on the spikes. I last sold at $2.60 and bought back at $1.95. Yes I’ve been holding the bag the last few months but ADMA has a history of volatility and the next round of upside volatility is coming. Waiting for a catalyst. This is a good rapidly growing company that sells a product that is in short supply and in high demand. A catalyst will come.
Eugene Lin ADMA 5 years ago #8$ADMA We need a blowout 3Q report to get out of the quagmire but I’m patient.
Eugene Lin ADMA 5 years ago #9 Eugene Lin ADMA 5 years ago #10$ADMA Nuveen Asset Management LLC grew its holdings in ADMA Biologics by 2,530.6% in the first quarter. Nuveen Asset Management LLC now owns 6,758,962 shares of the biotechnology company’s stock valued at $11,895,000 after purchasing an additional 6,502,025 shares during the period. Morgan Stanley boosted its stake in ADMA Biologics, Inc. by 85.0% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 380,576 shares of the biotechnology company’s stock after purchasing an additional 174,852 shares during the quarter.